Panel discussion on Supply Chain

  • Published: 29 Jun 2021

The COVID-19 pandemic has been magnifying the long-standing vulnerability of global pharma supply chain, forcing pharmaceutical industry to rethink and reshape its own in-/out-sourcing business model. Our Custom Synthesis Manager Jacopo Buzzanca reviews new “make-or-buy” decisions paradigms for developing a resilient and agile supply chain.

Check out the full article "COVID-19: A catalyst for the global pharma supply chain transformation" in the latest edition of #ChemistryToday at